Table 1.
Characteristics of included studies.
| References | Phase | Country | Control/belimumab | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean age (years) | Female (%) | UPCR | Proteinuria (g/24 h) | eGFR (mL/min/1.73m2) | Serum creatinine (μmol/L) | Serum albumin (mg/dL) | SLEDAI score | Sample size | Follow‐up (weeks) | |||
| Dooley et al. 20 | Phase III | Multinational | NA | NA | 1.8 ± 1.7/1.7 ± 1.2 | NA | 74.8 ± 23.9/74.7 ± 23.4 | NA | 12.9 ± 4.6/12.9 ± 4.3 | 92/85 | 52 | |
| BLISS‐LN 22 | Phase III | Multinational | 33.1 ± 10.6/33.7 ± 10.7 | 87.8/88.3 | 3.5 ± 3.6/3.2 ± 2.7 | 101.0 ± 42.7/100.0 ± 37.7 | NA | NA | 12.2 ± 4.8/12.5 ± 5.3 | 223/223 | 104 | |
| Atisha‐Fregoso et al. 21 | Phase II | USA | 32.3 ± 11.43/34.5 ± 9.14 | 81.8/90.5 | 3.4 ± 1.5/3.3 ± 2.5 | 92.7 ± 36.0/89.1 ± 33.9 | 90.2 ± 36.2/91.9 ± 41.4 | 2.96 ± 0.50/2.89 ± 0.61 | NA | 22/21 | 48 | |
Abbreviations: BLISS‐LN, Belimumab International Study in Lupus Nephritis; eGFR, estimated glomerular filtration rate; NA, not available; SLEDAI, systemic lupus erythematosus disease activity index; UPCR, urine protein‐to‐creatinine ratio.